Evommune (EVMN) Interest Expenses (2024 - 2026)

Evommune (EVMN) has reported Interest Expenses for 3 consecutive years, with $92.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses rose 45887.5% year-over-year to $92.0 million; the TTM figure through Mar 2026 stood at $92.0 million (changed N/A YoY), while the FY2025 annual figure was $54.5 million, up 6712.88% from the prior year.
• Interest Expenses climbed to $92.0 million in Q1 2026 per EVMN's latest filing, from -$43000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $92.0 million in Q1 2026 and bottomed at -$43000.0 in Q4 2025.
• Historically, Interest Expenses has averaged $16.5 million across 3 years, with a median of $108500.0 in 2024.
• Annual changes were most pronounced in 2025 — Interest Expenses slumped 816.67% — and 2026, when it jumped 45887.5%.
• Evommune's Interest Expenses stood at $6000.0 in 2024, then plunged by 816.67% to -$43000.0 in 2025, then surged by 213995.35% to $92.0 million in 2026.
• Business Quant data shows EVMN's Interest Expenses at $92.0 million in Q1 2026, -$43000.0 in Q4 2025, and $6.9 million in Q3 2025.